Yarrow Bioscience YARW
NASDAQ YARW
$29.11 -0.19 (-0.65%)
At close: Sep 9, 2026 · 4:00 PM EDT

Yarrow Bioscience (YARW) Non Operating Interest Expenses (2020 - 2021)

Yarrow Bioscience's (YARW) quarterly Non Operating Interest Expenses came in at $3.5 million in Q3 2021, up 218.13% on a YoY basis from $1.1 million in Q3 2020, and up 223.46% quarter-over-quarter from $1.1 million in Q2 2021.

Analysis

Yarrow Bioscience (YARW) Non Operating Interest Expenses (2020 - 2021) Analysis & Trends

Yarrow Bioscience (YARW) has reported Non Operating Interest Expenses for 2 consecutive years, with $3.5 million the latest figure, recorded in Q3 2021.

  • For the quarter ending Q3 2021, Non Operating Interest Expenses rose 218.13% year-over-year to $3.5 million; the trailing twelve-month figure through Jun 2022 stood at $3.5 million (down 20.85% YoY), and the FY2021 full-year result was $5.6 million, up 27.79% from the prior year.
  • Non Operating Interest Expenses grew to $3.5 million in Q3 2021 per YARW's latest filing, from $1.1 million in the prior quarter.
  • Across five years, Non Operating Interest Expenses topped out at $3.5 million in Q3 2021 and bottomed at $1.1 million in Q1 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Johnson & Johnson 643.26 Bn 622.50 Bn 17.26 Bn 281.00 Mn
2 AbbVie 443.31 Bn 436.74 Bn 12.70 Bn -
3 Merck 364.74 Bn 357.60 Bn 12.21 Bn -
4 Novartis Ag 266.46 Bn 258.77 Bn 11.24 Bn -462.00 Mn
5 Pfizer 158.57 Bn 146.88 Bn 10.94 Bn -
6 Sanofi 52.33 Bn 44.95 Bn 10.79 Bn -333.60 Mn
7 Revolution Medicines 43.79 Bn 43.79 Bn - 23.78 Mn
8 Incyte 25.23 Bn 20.69 Bn 1.57 Bn 582,000.00
9 United Therapeutics 21.67 Bn 19.01 Bn 683.80 Mn 2.90 Mn
10 Yarrow Bioscience 25.25 Mn 2.33 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2021 3.47 Mn
Jun 30, 2021 1.07 Mn
Mar 31, 2021 1.06 Mn
Dec 31, 2020 1.16 Mn
Sep 30, 2020 1.09 Mn
Jun 30, 2020 1.07 Mn
Mar 31, 2020 1.07 Mn